Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.
about
Crizotinib resistance: implications for therapeutic strategiesTackling ALK in non-small cell lung cancer: the role of novel inhibitorsOvercoming resistance to targeted therapies in NSCLC: current approaches and clinical applicationThe role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.Stereotactic body radiation therapy for oligoprogression of metastatic disease from gastrointestinal cancers: A novel approach to extend chemotherapy efficacy.Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.Radical irradiation of extracranial oligometastases.Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma.Successful treatment of hepatic oligometastases with stereotactic ablative radiotherapy and radiofrequency ablation in an anaplastic lymphoma kinase fusion-positive lung cancer patient.Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung CancerMaximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung CancerExtended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.Oligometastatic non-small-cell lung cancer: current treatment strategies.Radiation therapy for oligometastatic non-small cell lung cancer.New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer.Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancerIntegration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung CancerStereotactic body radiotherapy for oligoprogressive cancer.From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?Targeting ALK: Precision Medicine Takes on Drug Resistance.Hypopharyngeal and upper esophageal ulceration after cervical spine radiotherapy concurrent with crizotinib.Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients.Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII).Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience.Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma.Stereotactic Radiosurgery in the Management of Patients With Brain Metastases of Non-Small Cell Lung Cancer: Indications, Decision Tools and Future Directions.ALK inhibitors, resistance development, clinical trials.The current state of oligometastatic and oligoprogressive non-small cell lung cancer
P2860
Q26738381-69810576-3E71-4463-AA66-C41F1D6652C6Q26740329-07E75F09-CE2E-47EA-91CA-8F7376D87597Q26795556-1531C62D-E1D9-481F-B7E2-2A4C1DB5FABCQ30248748-804E50FE-A2B2-4CFB-9EC6-8B6969C910ACQ33591738-6EDA8D4E-B702-4F87-BA3A-E04ADB631F29Q33599443-0483707C-1ED2-469F-B3A7-223B0F8934DEQ33648808-5734AA8F-2132-4C1B-B085-71B123890FBEQ34124296-770A962B-1E9D-41D5-AB83-E330E8193E4BQ36594257-FC76FAB5-37C6-475E-A4CE-14CD40DABE59Q36644192-B0F7662F-07BF-47FB-8EEA-A74E09453B08Q37017020-FD154C02-5968-4684-A7C2-92573904CFB1Q37298872-FB90828E-D8AD-4EF1-BD7D-D90B9F6CBC89Q37350770-269EEDBC-EE49-45D6-8BBC-FA7B52229BE8Q37643566-120BFF7F-EFE9-4B43-9DDB-5214B876B676Q38463103-DC549035-6E42-40AD-AAC3-1D4E3E8A4989Q38576015-DE3DE113-50F0-4344-B74B-80A0802B1D1CQ38669285-177B823F-CCD4-4B69-9EB0-2C7783B6826AQ38739807-7CE33CE3-124B-4A6E-B6E7-4AB3DA948379Q38815297-CFDB8E08-6BA8-4F5F-A381-4E3C0F2FF12DQ38828319-CFD0055D-A55B-47B2-8523-0D83751E33A0Q38880324-3EC7DD51-FDC7-4003-A393-CBFFB4F39D2CQ38935913-D8D48D0D-EE5A-42C1-BD8D-ED731305FA6DQ39041541-D04453DE-E92A-485F-BBA4-05B066BEAE11Q39103431-69C5C6DD-C7E0-4F0F-94C6-58603AB689BDQ39263651-A74FEC81-B9AE-44A2-8426-1545993C21A4Q42279529-B62E5611-E536-46D4-8FD8-343DD05E5107Q46718088-B31EF9E7-0D24-46D1-A87C-95638FE403DDQ47253056-7D7D10B0-AA78-46D3-91C8-6016B238AC38Q47726463-22FBEE3B-CDAA-4243-AB73-D8CFB0D117E1Q47904167-B72CCD7F-8625-4C2C-B8AE-8F38D314EEEFQ53676596-44087B38-0DF3-4666-A84F-6F0670AF823FQ54942435-BFCB74AB-63C1-4838-84B0-F166971B4142Q55262467-C51185B2-CB12-4F18-B868-674B3C571463Q57172942-17ECE821-D880-4567-B803-DA0593128863
P2860
Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Stereotactic radiation therapy ...... patients receiving crizotinib.
@ast
Stereotactic radiation therapy ...... patients receiving crizotinib.
@en
Stereotactic radiation therapy ...... patients receiving crizotinib.
@nl
type
label
Stereotactic radiation therapy ...... patients receiving crizotinib.
@ast
Stereotactic radiation therapy ...... patients receiving crizotinib.
@en
Stereotactic radiation therapy ...... patients receiving crizotinib.
@nl
prefLabel
Stereotactic radiation therapy ...... patients receiving crizotinib.
@ast
Stereotactic radiation therapy ...... patients receiving crizotinib.
@en
Stereotactic radiation therapy ...... patients receiving crizotinib.
@nl
P2093
P2860
P1476
Stereotactic radiation therapy ...... patients receiving crizotinib.
@en
P2093
Andrew J Weickhardt
Benjamin Scheier
Brian D Kavanagh
D Ross Camidge
Gregory N Gan
Laurie E Gaspar
Robert C Doebele
P2860
P304
P356
10.1016/J.IJROBP.2013.11.010
P407
P577
2014-01-22T00:00:00Z